China | PharmaShots

Innovent and Eli Lilly Report Results of TYVYT (sintilimab) in P-II ORIENT-2 Study as 2L Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Innovent Receives the NMPA’s Approval for Byvasda (biosimilar, bevacizumab) to Treat Non-Small Cell Lung Cancer and Metastatic Colorectal Cancer in China

June 19, 2020July 3, 2020Shiwani Sharma

Shots: The NMPA has approved Byvasda for the treatment of patients with NSCLC and metastatic colorectal cancer. The approval follows TYVYT (sintilimab injection) [Read More...]

Roche’s Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China

March 5, 2020April 9, 2020Tuba Khan

Shots: China’s National Health Commission reports in its treatment guidelines that Roche’s Actemra can be used to treat coronavirus patients with serious lung [Read More...]

Alopexx Signs an Exclusive License Agreement with Beijing Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

Alopexx Signs an Exclusive License Agreement with Shenogen Pharma to Develop and Commercialize DI-LEU16-IL2 for B-Cell Lymphomas in China/Asia

March 5, 2020March 5, 2020Tuba Khan

Shots: Alopexx to receive up front, development & commercialization milestones along with royalties on sales. Beijing Shenogen Pharma get an exclusive license to [Read More...]

Eisai Signs a License Agreement with FUJI YAKUHIN for Dotinurad to Treat Hyperuricemia and Gout in China

February 26, 2020February 26, 2020Tuba Khan

Shots: FUJI YAKUHIN to receive up front, development & commercial milestones and will manufacture the formulation of dotinurad and supply it to Eisai [Read More...]

Vifor Pharma and Fresenius Kabi Collaborate to Establish Joint Venture in China

February 20, 2020February 20, 2020Tuba Khan

Shots: The companies partnered to form JV focusing on the marketing, market access, and medical affairs activities for the IV iron portfolio. Vifor [Read More...]

Inovio Collaborates with Beijing Advaccine to Advance the Development of INO-4800 Vaccine Targeting Coronavirus in China

January 31, 2020January 31, 2020Tuba Khan

Shots: Inovio is currently evaluating INO-4800 vaccine in P-I study assessing its safety and immunogenicity in the US and is supported by a [Read More...]

TB Alliance Collaborates with Hongqi Pharma to Commercialize New Therapy for Highly Drug-Resistant Forms of TB in China

January 20, 2020January 20, 2020Tuba Khan

Shots: Hongqi to get a license to commercialize pretomanid as part of the three-drug “BPaL” regimen to treat a highly drug-resistant form of [Read More...]

Federal Circuit to Dismiss Halt Sales of Amgen’s Mvasi (biosimilar, bevacizumab-awws) in the US

Amgen Signs an Agreement with BeiGene for the Expansion of its Oncology Footprints in China

January 3, 2020January 3, 2020Shiwani Sharma

Shots: Amgen acquires 20.5% stake in BeiGene for ~$2.8B in cash, with $174.85/share representing 36% premium. BeiGene will commercialize Xgeva, Kyprolis, and Blincyto [Read More...]

Zai Lab and Novocure’s Optune Receive NMPA’s Innovative Medical Device Designation for its Tumor Treating Field Delivery System

Zai Lab’s Zejula (niraparib) Receives NMPA’s Approval as Maintenance Therapy for Patients with Recurrent Ovarian Cancer in China

December 30, 2019December 30, 2019Shiwani Sharma

Shots: Zejula (niraparib) is an oral once-daily poly (ADP-ribose) polymerase (PARP) inhibitor used as a maintenance therapy for adult patients with recurrent epithelial [Read More...]

Clover Reports Dosing of SCB-808 (biosimilar, etanercept) in P-III Trial in China

December 30, 2019February 12, 2020Shiwani Sharma

Shots: The P-III study involves assessing of SCB-808 vs Enbrel in patients with AS (axSpA) via SC administration SCB-808 is being developed in [Read More...]